PMID- 32067719
OWN - NLM
STAT- MEDLINE
DCOM- 20200506
LR  - 20200506
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 107
IP  - 4
DP  - 2020 Apr
TI  - [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
PG  - 447-457
LID - S0007-4551(20)30031-X [pii]
LID - 10.1016/j.bulcan.2019.11.014 [doi]
AB  - The advent of molecular biology resulted in the discovery of new oncogenes that 
      have led to the development of targeted therapies for the management of cancer 
      patients. The development of these therapies has improved the prognosis of 
      patients in various tumour localizations. The TRK receptor (tropomyosin receptor 
      kinase) is a transmembrane receptor with a tyrosine kinase activity that plays a 
      role in both cell proliferation and the physiology of the nervous system. Fusions 
      involving the NTRK gene, which codes for this receptor, have been found in 
      different types of solid tumours and lead to its constitutional activation. These 
      fusions, however uncommon, are mainly found in rare pediatric tumours but can 
      also be encountered in digestive cancers with high prevalence (such as colorectal 
      cancer, especially in case of microsatellite instability, with a frequency of 2.5 
      to 38.5 %) or in aggressive cancers (such as pancreatic cancer). Therapies 
      targeting TRK, such as larotrectinib or entrectinib, have shown significant 
      response rates, usually greater than 6 months, for tumours from various primary 
      sites presenting NTRK fusions and refractory to standard therapies. These fusions 
      can be detected by different methods: immunohistochemistry, FISH (fluorescence in 
      situ hybridization) as well as NGS (next generation sequencing). The intent of 
      this review is to report on current knowledge on NTRK fusions in oncology and to 
      discuss the role of these fusions in digestive cancers and potential therapeutic 
      implications.
CI  - Copyright (c) 2020 Societe Francaise du Cancer. Published by Elsevier Masson SAS. 
      All rights reserved.
FAU - Ouali, Kaissa
AU  - Ouali K
AD  - AP-HP, hopital Saint-Antoine, service d'oncologie medicale, 75012 Paris, France.
FAU - Pellat, Anna
AU  - Pellat A
AD  - AP-HP, hopital Saint-Antoine, service d'oncologie medicale, 75012 Paris, France; 
      Sorbonne universite, Paris, France.
FAU - Cohen, Romain
AU  - Cohen R
AD  - AP-HP, hopital Saint-Antoine, service d'oncologie medicale, 75012 Paris, France; 
      Sorbonne universite, Paris, France.
FAU - Svrcek, Magali
AU  - Svrcek M
AD  - Sorbonne universite, Paris, France; AP-HP, hopital Saint-Antoine, departement 
      d'anatomo-pathologie, 75012 Paris, France.
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
AD  - Centre Jean Perrin, departement d'anatomo-pathologie, 63000 Clermont-Ferrand, 
      France.
FAU - Andre, Thierry
AU  - Andre T
AD  - AP-HP, hopital Saint-Antoine, service d'oncologie medicale, 75012 Paris, France; 
      Sorbonne universite, Paris, France. Electronic address: thierry.andre@aphp.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Fusions NTRK : une nouvelle piste dans les cancers digestifs ?
DEP - 20200214
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Benzamides)
RN  - 0 (ETV6-NTRK3 fusion protein, human)
RN  - 0 (Indazoles)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (oncogene protein trk)
RN  - EC 2.7.10.1 (Receptor, trkA)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.10.1 (Receptor, trkC)
RN  - EC 2.7.10.1 (tropomyosin-related kinase-B, human)
RN  - L5ORF0AN1I (entrectinib)
RN  - PF9462I9HX (larotrectinib)
SB  - IM
MH  - Benzamides/therapeutic use
MH  - Colorectal Neoplasms/drug therapy/genetics
MH  - Gastrointestinal Neoplasms/*drug therapy/*genetics
MH  - *Gene Fusion
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Indazoles/therapeutic use
MH  - Membrane Glycoproteins/genetics
MH  - Nerve Growth Factors/*genetics
MH  - Oncogene Proteins/*genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Pancreatic Neoplasms/drug therapy/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyrazoles/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - Receptor, trkA/genetics
MH  - Receptor, trkB/genetics
MH  - Receptor, trkC/genetics
OTO - NOTNLM
OT  - Cancers digestifs
OT  - Entrectinib
OT  - Larotrectinib
OT  - Microsatellite instability
OT  - Neurotrophic Tropomyosin Receptor Kinase (NTRK)
EDAT- 2020/02/19 06:00
MHDA- 2020/05/07 06:00
CRDT- 2020/02/19 06:00
PHST- 2019/08/25 00:00 [received]
PHST- 2019/11/11 00:00 [revised]
PHST- 2019/11/16 00:00 [accepted]
PHST- 2020/02/19 06:00 [pubmed]
PHST- 2020/05/07 06:00 [medline]
PHST- 2020/02/19 06:00 [entrez]
AID - S0007-4551(20)30031-X [pii]
AID - 10.1016/j.bulcan.2019.11.014 [doi]
PST - ppublish
SO  - Bull Cancer. 2020 Apr;107(4):447-457. doi: 10.1016/j.bulcan.2019.11.014. Epub 
      2020 Feb 14.